Nocturnal acid breakthrough: Clinical significance and management

被引:16
作者
Ang, Tiing Leong [1 ]
Fock, Kwong Ming [1 ]
机构
[1] Changi Gen Hosp, Dept Med, Div Gastroenterol, Singapore 529889, Singapore
关键词
acid breakthrough; proton pump inhibitors;
D O I
10.1111/j.1440-1746.2006.04717.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nocturnal acid breakthrough is seen in more than 70% of Helicobacter pylori-negative patients taking long-term proton pump inhibitors (PPI). It is defined as an intragastric pH of less than 4 for at least 60 consecutive minutes during the overnight period in patients on PPI therapy. It occurs as a result of the recovery of intragastric acidity. Nocturnal acid breakthrough can be clinically significant in patients with complicated gastroesophageal reflux disease, Barrett's esophagus and esophageal motility disorders because of the potential for continued esophageal mucosal injury. To decrease nocturnal acid breakthrough, for patients on once daily PPI, treatment should be stepped up to twice daily. For patients already on twice daily PPI, nocturnal histamine-2 receptor antagonists may be added, but the long-term effectiveness remains debatable as patients may develop tolerance over the course of time. New PPI with a longer half-life may decrease nocturnal acid breakthrough.
引用
收藏
页码:S125 / S128
页数:4
相关论文
共 26 条
[1]   Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects:: effects of different regimens [J].
Adachi, K ;
Komazawa, Y ;
Fujishiro, H ;
Mihara, T ;
Ono, M ;
Yuki, M ;
Kawamura, A ;
Azharul, M ;
Rumi, K ;
Amano, Y ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (09) :830-835
[2]   Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough [J].
Fackler, WK ;
Ours, TM ;
Vaezi, MF ;
Richter, JE .
GASTROENTEROLOGY, 2002, 122 (03) :625-632
[3]   Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease [J].
Fock, KM ;
Talley, N ;
Hunt, R ;
Fass, R ;
Nandurkar, S ;
Lam, SK ;
Goh, KL ;
Sollano, J .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (04) :357-367
[4]  
Fouad YM, 1999, ALIMENT PHARM THERAP, V13, P1467
[5]   Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life:: effects on intragastric pH and comparison with esomeprazole in healthy volunteers [J].
Galmiche, JP ;
Des Varannes, SB ;
Ducrotté, P ;
Sacher-Huvelin, S ;
Vavasseur, F ;
Taccoen, A ;
Fiorentini, P ;
Homerin, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (06) :655-662
[6]   Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole [J].
Gillen, D ;
Wirz, AA ;
Neithercut, WD ;
Ardill, JES ;
McColl, KEL .
GUT, 1999, 44 (04) :468-475
[7]   Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough [J].
Hammer, J ;
Schmidt, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (10) :1105-1110
[8]  
Hatlebakk JG, 1998, ALIMENT PHARM THERAP, V12, P1235
[9]   Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers [J].
Hunt, RH ;
Armstrong, D ;
James, C ;
Chowdhury, SK ;
Yuan, YH ;
Fiorentini, P ;
Taccoen, A ;
Cohen, P .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09) :1949-1956
[10]  
Ishizaki T, 1999, ALIMENT PHARM THERAP, V13, P27